Surrozen secures FDA clearance for SZN-8141 clinical trial

Trial StartSZN-8141Positive

AI Analysis

Summary

Surrozen has received FDA clearance of its IND application for SZN-8141 to initiate clinical trials in diabetic macular oedema. This regulatory milestone allows the company to begin human testing of the investigational drug.

Clinical Trial Data

Outcome Details

FDA cleared IND application

Importance:5/10

Sentiment:

0.70

FDA clearanceIND applicationdiabetic macular oedemaclinical trial

Related Companies

$TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on October 5, 2026 9:51 AM

Read Original